Publication | Open Access

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line TreatmentPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyGynecology OncologyEndocrine-related CancerOvarian Cancer